ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Imbruvica/Venclyxto tops Gazyva plus chemo in first-line CLL/SLL
June 17, 2021Johnson & Johnson’s BTK inhibitor Imbruvica plus AbbVie and Roche’s Vencylxto demonstrated superiority over Gazyva plus chemotherapy in a new Phase III study. -
TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab in Combination with Ukoniq (umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia and Smal
May 26, 2021TGTX today announced that FDA has accepted the Biologics License Application (BLA) for ublituximab as a treatment for patients with chronic lymphocytic leukemia (CLL) and SLL.
Pharma Sources Insight January 2025
